Clinigen Group (CLIGF) Stock Price, News & Analysis

Company Overview

Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.

Key Stats

• Today's Range: $8.02 to $8.02
• 50-Day Range: $8.02 to $8.02
• 52-Week Range: $8.02 to $11.56
• Volume: N/A
• Average Volume: 8,620 shs
• Market Capitalization: $1.07 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CLIGF Stock Analysis - Frequently Asked Questions

How have CLIGF shares performed this year?

Clinigen Group's stock was trading at $8.0157 on January 1st, 2025. Since then, CLIGF stock has increased by 0.0% and is now trading at $8.0157.
View the best growth stocks for 2025 here.

How do I buy shares of Clinigen Group?

Shares of CLIGF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 4/26/2025
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Private households
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:CLIGF
• Previous Symbol: NASDAQ:CLIGF
• CIK: N/A
• Web: www.clinigengroup.com
• Phone: 44-12-8349-5010
• Fax: 01283 495011
• Employees: 1,069
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $704.71 million
• Price / Sales: 1.51
• Cash Flow: $1.43 per share
• Price / Cash Flow: 5.60
• Book Value: $4.52 per share
• Price / Book: 1.77

Miscellaneous

• Outstanding Shares: 133,030,000
• Free Float: N/A
• Market Cap: $1.07 billion
• Optionable: Not Optionable
• Beta: 0.49